Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

Randomized, Double-Blind Study Targets Biomarker-Defined Population

BERKELEY HEIGHTS, N.J., Aug. 21 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the first patients have been enrolled in the Company's confirmatory Phase 3 trial of Genasense (oblimersen sodium) Injection in advanced melanoma. The trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA will accrue approximately 300 patients and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Accrual is expected to take approximately 18 months, with initial data expected shortly thereafter.

AGENDA is designed to confirm the safety and efficacy of Genasense when combined with DTIC in patients who have not previously received chemotherapy. Genta's prior Phase 3 trial of this drug combination had shown that maximal benefit occurred in patients with normal baseline LDH, a blood enzyme that strongly correlates with outcome. The AGENDA study is limited to patients whose baseline LDH is less than 0.8 times the upper limit of normal. Analysis of that trial suggested that patients in this group achieved a significantly superior outcome (see table below).

"Genasense plus dacarbazine yielded superior results in a large randomized trial," said Dr. Agop Bedikian, Professor of Medicine at the M.D. Anderson Cancer Center, Houston, TX, who was the lead author on the publication of the previous Genasense trial. "Our center is pleased to have entered the first patient onto this important new study that seeks to extend those initial results using a biomarker t
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Levi & ... Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning possible violations ... issued by the Company in connection with its study ... TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. ... or by telephone at (212) 363-7500, toll-free: (877) ...
(Date:3/27/2015)... , March 27, 2015  Holographic Optical Technologies of ... field of holographic medical imaging, is entering the world ... campaign. Launching on April 20 th , 2015, the ... Pro. The 8-inch and 22-inch displays will allow consumers ... the first time. In addition to the two displays, ...
(Date:3/27/2015)... 2015 A new report from Kalorama Information says ... – Chile , Colombia ... for IVD firms.  The healthcare research firm said that while ... for the Latin American continent with a population of over ... operations. However, the country,s regional economic clout does not necessarily ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... BETHLEHEM, Pa., Oct. 26 A landmark study ... French hospitals over a two-year period has confirmed ... offer significantly better protection against accidental needlestick injuries ... as semi-automatic (push-button) devices or those with manually ...
... Md., Oct. 26 MedAvante, Inc., the leader ... (CNS) disorders, and Rexahn Pharmaceuticals, Inc. (NYSE Amex: ... company developing and commercializing potential best in class ... use MedAvante ,s Remote Centralized Ratings™ in their ...
Cached Medicine Technology:Study Confirms Passive Safety Devices Are Most Effective in Needlestick Injury Prevention 2Study Confirms Passive Safety Devices Are Most Effective in Needlestick Injury Prevention 3Study Confirms Passive Safety Devices Are Most Effective in Needlestick Injury Prevention 4Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study 2Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study 3
(Date:3/29/2015)... March 29, 2015 Adults who are ... promote nationally on the web can now use the ... insurance quotes can now be explored while researching the ... , Learning the differences between what a term policy ... a challenge for some men and women. Insurers typically ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... Washington, D.C. USA (PRWEB) March 29, 2015 ... Afro Health Link platform provides basic health ... them the opportunity to discuss these challenges as ... them. Afro Health Link addresses six medical conditions ... and encourage users to engage in conversations around ...
(Date:3/29/2015)... 29, 2015 North American Seminars receives ... Online Continuing Education Courses . , Utilizing ... CME - TPTA, approval # 56399TX      , ... the shoulder complex - 10.5 hours - Texas Board ... Examination and Treatment of the SI Joint - 10 ...
(Date:3/28/2015)... 2015 Coffee could not only perk you ... from gum disease, researchers have found. , They found that ... Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, then, ... Boston Univ. Henry M. Goldman School of Dental Medicine explored ... issue of the Journal of Periodontology. , “This is the ...
Breaking Medicine News(10 mins):Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2
... ... injury attorney, results in payment to an underage passenger hurt in a vehicle crash after ... ... Mark Gemma underscores the liability homeowners face when they allow underage drinking in ...
... ... latest information about clinics, camps, academies and events at Sea Colony - The Premier ... just north of Ocean City, Maryland. , ... Sea Colony, Bethany Beach, Del. (PRWEB) February 12, 2010 -- ...
... ANDREWS, Texas , Feb. 11 It took the jury ... for Anne Mitchell, RN , defendant in the criminal trial that ... trial. Mitchell faced a third-degree felony charge in Texas of ... Board for what she believed was unsafe patient care. Mitchell is a ...
... coronary artery , THURSDAY, Feb. 11 (HealthDay News) -- Former ... Thursday evening in a New York City hospital after he ... , The 63-year-old Clinton, who underwent quadruple bypass surgery in ... reports. , "Today President Bill Clinton was admitted to ...
... , , , ... 11 /PRNewswire-Asia-FirstCall/ -- China Cord Blood,Corporation ("CCBC" or ... leading provider of,cord blood collection, laboratory testing, hematopoietic ... that the Securities and,Exchange Commission ("SEC") declared the Company,s ...
... stress disorder (PTSD) threatens to overload healthcare and ... cases rises and existing treatments are not sufficiently ... technology, such as virtual reality, to alleviate the ... solutions are explored in a special issue of ...
Cached Medicine News:Health News:Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma 2Health News:New SeaColonyTennis.net Launches to Promote World-Class Tennis Programs at Sea Colony 2Health News:Not Guilty - Texas Jury Acquits Winkler County Nurse 2Health News:Not Guilty - Texas Jury Acquits Winkler County Nurse 3Health News:Ex-President Clinton Undergoes Heart Procedure 2Health News:China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC 2Health News:Virtual reality and other technologies offer hope 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: